PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Journal of Advanced Research1 citationsOpen Access

Asprosin-driven metabolic-epigenetic rewiring attenuates mesenchymal stem cell senescence with therapeutic benefits for infarcted hearts

View Full Paper
ZZZhengbin ZhangChinese PLA General HospitalZWZiqian WangChinese PLA General HospitalLZLiwen ZhuChinese PLA General Hospital

Key Points

  • Asprosin rejuvenates mesenchymal stem cells, counteracting senescence effectively.
  • This metabolic-epigenetic interplay showcases the potential for regenerative therapies targeting heart diseases.
  • The study emphasizes the 'Glycolysis-Lactylation-Epigenetics' axis as a transformative strategy in treatment.
  • Findings indicate that enhancing asprosin pathways may lead to significant therapeutic advancements.

Abstract

Asprosin is a novel MSC-specific rejuvenation factor that antagonizes senescence through metabolic-epigenetic interplay. Targeting the asprosin-driven "Glycolysis-Lactylation-Epigenetics" axis offers a transformative strategy to enhance MSC-based therapies for ischemic heart disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69a75eb3c6e9836116a298fehttps://doi.org/10.1016/j.jare.2026.01.073
Ask AI
Helpful
Bookmark
Share
View Full Paper